盐酸法舒地尔对经皮冠状动脉介入术中无复流的预防作用

Preventive effect of hydroxyfasudil on no-reflow in percutaneous coronary intervention

目的观察急性冠状动脉综合征患者经皮冠状动脉介入术(percutaneous coronary intervention,PCI)前应用盐酸法舒地尔预防无复流的作用。方法拟行PCI术急性冠状动脉综合征患者240例,随机分为观察组和对照组各120例,2组术前均应用相同剂量的阿司匹林、阿托伐他汀钙片、美托洛尔、氯吡格雷等药物,观察组术前30min静脉滴注盐酸法舒地尔30mg+生理盐水100mL,对照组术前30min静脉滴注生理盐水100mL。PCI术中根据TIMI血流分级判定2组无复流发生情况。结果观察组无复流发生率(3.33%)低于对照组(12.50%)(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论 PCI术前应用盐酸法舒地尔可预防无复流的发生。

Objective To observe the effect of hydroxyfasudil on preventing no-flow in percutaneous coronary intervention （PCI） in patients with acute coronary syndrome （ACS）. Methods A total of 240 patients undergoing PCI for ACS were randomly divided into experimental group and control group, with 120 patients in each group. Besides the same loading dose of aspirin, statin, metoprolol and clopidogrel, experimental group received intravenous injection of hydroxyfasudil 30 mg dissolved in 0.9% sodium chloride injection 100 mL and control group received placebo of 0.9% sodium chloride injection 30 minutes before operation. The occurrence of no-reflow was evaluated according to the flowing grade in thrombolysis in myocardial infarction. Results The incidence rate of no-reflow was 3. 33% in experimental group, lower than that in control group （12.50%） （P〈0.05）. There was no significant difference in the incidence of adverse reactions between two groups （P〉0.05）. Conclusions Preoperative use of hydroxyfasudil can prevent the occurrence of no-fellow.